Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Genomics Receives Notification of Nasdaq Non-Compliance

NEW YORK (GenomeWeb) – Rosetta Genomics said today that it has received notification from the Nasdaq that it no longer meets the exchange's stockholder equity listing requirement.

According to Rosetta, it has received a letter from the Nasdaq indicating that it is not in compliance with a listing rule requiring a minimum of $2.5 million in stockholders' equity. The company said it has 45 days from Oct. 24 to submit a specific plan to regain compliance with this requirement. If the plan is accepted, the Nasdaq may provide Rosetta with up to 180 calendar days from the date of the notification to regain compliance.

Earlier this year, Rosetta effected a 1-for-12 reverse stock split after failing to meet the Nasdaq's $1 minimum bid price requirement.

During early morning trading, shares of Rosetta were up $.01 at $.80.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.